Largest Catalent site will expand cold chain offerings; First phase completed for Avid's CA upgrade
A Philadelphia Catalent site will get an increase in cold-chain packaging capabilities to gear up for any future increases in gene and cell therapies.
The site will be expanded by 20,000 square feet and add an additional seven temperature-controlled processing suites. Those suites can either be in refrigerated or frozen conditions to match the needs of the drugs handled. There will also be more storage space, and the suites are designed for small-scale batches of commercial products.
The upgrade to support increased demand is set to be completed by the end of the current fiscal quarter.
“The specifically designed packaging areas not only provide optimal commercial opportunities for drug developers, but also the safest working conditions for employees in terms of air exchange rates, carbon dioxide monitoring, and ultraviolet air sanitization,” GM Ann McMahon said in a statement.
The site is Catalent’s largest in its network and includes 200,000 square feet.
First phase completed for Avid’s CA upgrade
Avid Bioservices has opened a second downstream processing suite in its Myford North site in Tustin, CA.
The company is now actively scheduling new businesses into the suite. The construction was the first phase of a two-part expansion and brings in a possibility of $270 million in revenue for its mammalian cell business. It will also parlay the upgrades into expansion into the cell and gene therapy market.
The second part of the construction plan is already underway. That will feature a manufacturing train that includes upstream and downstream processing suites, and 53,000 square feet of viral vector development.
Editor’s Note: For more news and exclusive coverage from the manufacturing beat, subscribe to the Endpoints Manufacturing weekly report in your reader profile.